Senti Biosciences Holdings, Inc. (SNTI): Capital Expenditures
$196.0K
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
-83.2%
3-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $196.0K | +653.8% | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $26.0K | -99.8% | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | $12.04M | -70.9% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $41.37M | +646.4% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $5.54M | n/a | 2023-03-22, From 2021-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $196.0K | +653.8% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $107.0K | n/m |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $1.04M | n/a |
| AIM ImmunoTech Inc. (AIM) | 2024-12-31 | $18.0K | n/a |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $0 | -100.0% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $77.0K | +18.5% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $44.0K | -45.0% |
| Prokidney Corp. (PROK) | 2025-12-31 | $15.20M | -48.5% |
| Pluri Inc. (PLUR) | 2026-06-30 | $633.0K | -60.9% |
Compare SNTI, ENTX, INMB, AIM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗